Idorsia – building momentum in 2023

Octavian Seminar – 14 Jan 2023

The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”, “pending” or “anticipates” or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company’s investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company’s existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

"Our achievements in 2022 provide the foundation for our success in 2023."

Jean-Paul Clozel
Chief Executive Officer

2022 was a transformative year for Idorsia



QUVIVIQ™ (daridorexant)

QUVIVIQ™

daridorexant 25mg, 50mg tablets

Daridorexant is available in the US and the first countries in Europe under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union and in Switzerland and is currently under review in Canada.

idorsia

QUVIVIQ has the highest level of satisfaction

Level of Satisfaction with Insomnia Treatments



Source: Q3 2022 HCP ATU

Daridorexant is available in the US and the first countries in Europe under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union and in Switzerland and is currently under review in Canada.

QUVIVIQ has the highest level of satisfaction with access being the strongest barriers to prescribing

Level of Satisfaction with Insomnia Treatments



Barriers to Prescribing Treatments



Source: Q3 2022 HCP ATU

Daridorexant is available in the US and the first countries in Europe under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union and in Switzerland and is currently under review in Canada.

HCP awareness of QUVIVIQ continues to grow



Source: HCP ATU – October 2022 Pulse

Daridorexant is available in the US and the first countries in Europe under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union and in Switzerland and is currently under review in Canada.

Strong & growing demand…





Source: IQVIA + VitaCare Pharmacy Services

Daridorexant is available in the US and the first countries in Europe under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union and in Switzerland and is currently under review in Canada.

…along with sustained growth in our writer base





Source: IQVIA + VitaCare dispenses through 2022-11-30

Daridorexant is available in the US and the first countries in Europe under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union and in Switzerland and is currently under review in Canada.

Quickly becoming the leading branded insomnia medicine in NBRx – with accelerating CBRx

New to brand prescriptions (NBRx)



Continued brand prescriptions (CBRx)



Source: IQVIA + Vitacare Fills data

Daridorexant is available in the US and the first countries in Europe under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union and in Switzerland and is currently under review in Canada.

On track to become a global brand

QUVIVIQ™
daridorexant 25mg, 50mg tablets

New Drug Submission under review with Health Canada

Launched in the US

Approved by the European Medicines Agency and MHRA

Launched in Germany and Italy with further EU countries to follow

Approved by Swissmedic

Phase 3 study successful in Japan; filing expected in H2 2023

Daridorexant is available in the US and the first countries in Europe under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union and in Switzerland and is currently under review in Canada.

idorsia

QUVIVIQ off to a great start in Germany



Source: IQVIA

Daridorexant is available in the US and the first countries in Europe under the tradename QUVIVIQ. In addition, daridorexant is approved throughout the European Union and in Switzerland and is currently under review in Canada.

PIVLAZ™ (clazosentan)

PIVLAZ
clazosentan

Clazosentan is only marketed in Japan under the tradename PIVLAZ™. In other countries, clazosentan is investigational, in development and not approved or marketed.

Successful launch in Japan

PIVLAZ clazosentan

Approved in January 2022, launched in April 2022

Expert engagement to improve treatment of aSAH patients



>95%

of target accounts **are ordering** PIVLAZ

~25%

of aSAH **patients treated** with PIVLAZ in November 2022

Clazosentan is only marketed in Japan under the tradename PIVLAZ™. In other countries, clazosentan is investigational, in development and not approved or marketed.

idorsia

Our drug discovery engine continues to deliver

Compound	Mechanism of action	Target indication	Status
QUVIVIQ™ (daridorexant)	Dual orexin receptor antagonist	Insomnia	Commercially available as QUVIVIQ in the US and the first countries in Europe. Approved in Switzerland. Under review in Canada. Phase 3 in Japan successful – filing expected in H2 2023. Phase 2 in pediatric insomnia – recruiting.
PIVLAZ™ (clazosentan)	Endothelin receptor antagonist	Cerebral vasospasm associated with aneurysmal subarachnoid hemorrhage	Commercially available as PIVLAZ in Japan. Global Phase 3 – complete.
Aprocitentan*	Dual endothelin receptor antagonist	Difficult-to-control hypertension	NDA submitted, MAA in preparation
Lucerastat	Glucosylceramide synthase inhibitor	Fabry disease	Phase 3 primary endpoint not met, Open Label Extension study ongoing
Selatogrel	$P2Y_{12}$ inhibitor	Suspected acute myocardial infarction	Phase 3 recruiting
Cenerimod	$S1P_1$ receptor modulator	Systemic lupus erythematosus	Phase 3 recruiting
ACT-1004-1239	ACKR3 / CXCR7 antagonist	Multiple sclerosis	Phase 2 in preparation
Sinbaglustat	GBA2/GCS inhibitor	Rare lysosomal storage disorders	Phase 1 complete
ACT-1014-6470	C5aR1 antagonist	Immune-mediated disorders	Phase 1
ACT-777991	CXCR3 antagonist	Recent-onset Type 1 diabetes	Phase 1
IDOR-1117-2520	Undisclosed	Immune-mediated disorders	Phase 1

* In collaboration with Janssen Biotech to jointly develop aprocitentan, Janssen Biotech has sole commercialization rights worldwide.

Neurocrine Biosciences has a global license to develop and commercialize ACT-709478 (NBI-827104), Idorsia's novel T-type calcium channel blocker. ACT-709478 was investigated in a Phase 2 study for the treatment of a rare form of pediatric epilepsy. The study did not meet the primary endpoint. ACT-709478 was generally well tolerated. Neurocrine continues to analyze the data generated in the study to determine next steps.

Aprocitentan has significant and sustained efficacy



Placebo

Aprocitentan 12.5 mg

Aprocitentan 25 mg

***Primary endpoint**
P=0.0042 for aprocitentan 12.5 mg vs placebo
P=0.0046 for aprocitentan 25 mg vs placebo

†Key secondary endpoint
P<0.0001 for aprocitentan 25 mg vs placebo

Bars are standard error of the mean
Values are offset from each other for readability

The most frequent adverse event was fluid retention which was reported more frequently with aprocitentan than with placebo in a dose-dependent fashion

Aprocitentan is investigational, in development and not approved or marketed in any country.

Efficacy confirmed by Ambulatory BP monitoring at Week 4 (DB Part 1)





Bars are standard error of the mean
Values are offset from each other for readability

Aprocitentan is investigational, in development and not approved or marketed in any country.

Aprocitentan for difficult-to-control hypertension

New mode of action in systemic hypertension

Aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated

- New drug application (NDA) filed with the US FDA Dec 2022
- Applications to other health authorities anticipated in 2023
- Janssen to commercialize – Idorsia entitled to tiered royalties





idorsia

Aprocitentan is investigational, in development and not approved or marketed in any country.

Selatogrel – Potential to change the way AMI is treated



‘Fast’ onset of action

‘Short’ duration of action

Potent and highly selective $P2Y_{12}$ inhibitor

Suitable for subcutaneous injection

Selatogrel is investigational, in development and not approved or marketed in any country.

Treatment approach in Phase 3 SOS-AMI



Onset of AMI symptoms

Self-administer selatogrel using autoinjector at symptom onset

Patient calls for emergency service or travels to hospital

First medical contact



Emergency medical care follow-up at hospital

Slowing or stopping of the heart attack

Our hope: Early intervention leads to better short-term and long-term outcome

Selatogrel is investigational, in development and not approved or marketed in any country.

idorsia

CARE Phase 2b delivered according to promise

4 mg cenerimod

selected for Phase 3

Potential to be the first new generation oral drug for SLE



- Clinically meaningful improvement in disease activity
  - Treatment effect increases over time
  - Treatment effect is increased in patients with greater disease severity and high IFN-1 gene signature at baseline
- Favorable safety profile
  - Low rate of serious AEs and infections

Cenerimod is investigational, in development and not approved or marketed in any country.

OPUS: Confirmatory program design

Two Phase 3 multicenter, randomized, double-blind, placebo-controlled, parallel-group studies to evaluate the **efficacy, safety, and tolerability** of cenerimod in adult patients with moderate-to-severe SLE on top of background therapy



Cenerimod is investigational, in development and not approved or marketed in any country.

Profitability target



The company is committed to reach sustainable profitability in 2025 with global revenue above CHF 1 billion

Based on:

- Sales of QUVIVIQ
- Sales of PIVLAZ in Japan
- Tiered royalties on aprocitentan

Excluding unforeseen events

Momentum building catalysts in 2023



†Effective January 15, 2023, QUVIVIQ will be covered at parity to the other branded dual orexin receptor antagonist products for the Express Scripts National Preferred Formulary.